EUSA Pharma

About EUSA Pharma

EUSA Pharma is a specialty pharma company with a strong and growing portfolio of specialty hospital medicines. It has been built through the acquisition of Talisker Pharmaceuticals in July 2006 and OPi in March 2007.

Our primary marketed products Erwinase®, Rapydan®, Kidrolase®, Fomepizole and Xenazine, are focused on the areas of oncology, pain control and critical care. In addition, we have an active late-stage development pipeline, which includesing candidates in targeting rheumatoid arthritis and Alzheimer’s disease, schizophreniathe prevention and treatment of infected skin ulcers and local post-surgical pain control.

During 2007 EUSA Pharma extended its transatlantic commercialization infrastructure, has established a marketing capability in the big five largest European markets (France, Germany, Italy, Spain and the UK) as well as in Scandinavia, Benelux, Austria, Ireland and Portugal. In additionEUSA also established a commercial presence in North America, and supplies Erwinase® is made available to investigators under a Treatment IND in the United States.

In parallel EUSA is actively pursuing merger and acquisition activities and other transactions are underway to further develop its effective US commercialization capability facilitating to provide further broader access to the North American specialty pharmaceutical market.